List of Otezla drug patents

Otezla is owned by Amgen Inc.

Otezla contains Apremilast.

Otezla has a total of 11 drug patents out of which 0 drug patents have expired.

Otezla was authorised for market use on 21 March, 2014.

Otezla is available in tablet;oral dosage forms.

Otezla can be used as treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule, use of otezla (apremilast) for the treatment of psoriatic arthritis, treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with active psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for inhibiting pde4; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

The generics of Otezla are possible to be released after 29 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(10 months from now)

US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
Mar, 2023

(a month from now)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(a month from now)

US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
Mar, 2023

(a month from now)

US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(a month from now)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Mar, 2023

(a month from now)

US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(a month from now)

US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(a month from now)

US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
May, 2034

(11 years from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 20, 2024
Orphan Drug Exclusivity (ODE) Jul 19, 2026
M Apr 10, 2023

Drugs and Companies using APREMILAST ingredient

Market Authorisation Date: 21 March, 2014

Treatment: Use of otezla (apremilast) for inhibiting pde4; Treatment of adult patients with oral ulcers associated with behcet's disease; Treatment of adult patients with active psoriatic arthritis; Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Use of otezla (apremilast) for the treatment of psoriasis; Treatment of psoriasis using a dosage titration schedule; Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; Treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent

Dosage: TABLET;ORAL

How can I launch a generic of OTEZLA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic